Table 1.

Targeting peptides that studied in the treatment of cancers

Peptide	Cancer	Cellular target	Outcomes	References
M-CTX-Fc	Glioblastoma	CD44	Increased bioavailability of DOX in U251MG-P1 glioblastoma cells. It was carried by liposomes	[30]
TAT	Nasopharyngeal carcinoma	CPP	Reduce the drug resistance and side effects of cisplatin	[34]
BR2	Cervical cancer, melanoma and colon cancer	CPP	Antiproliferative effects on HeLa, HCT116 and B16-F10 cells	[35]
cRGD	TNBC	αvβ3 integrin	Suppressed tumor growth with no noticeable side effects	[46]
cRGD	Lung	αvβ3 integrin	Increased bioavailability and anticancer effects of Dox	[47]
CTL-1	Glioma	Fibronectins	Increased inhibitive effects of PTX	[49]
MRP	Liver cancer	MMP-2	Increased antifibrotic effects of Pirfenidone	[50]
MTP-NRP1	Glioblastoma	NRP-1	Decreased cancer tissue angiogenesis due to this intervention	[51, 52]
SP2043	Breast cancer	IGF1R	Biomimetic peptide inhibits growth and metastasis of breast cancer by inhibiting the lymphangiogenesis and angiogenesis	[53]
TAT-ELP1-L12	Pancreatic adenocarcinoma	CPP	Enhance the antitumor effects of L12 peptide through dual targeting	[62]
GLVATVKEAGRSIHEIPREEL	Lymphoma	BCL6	Maintain the corepressor activity of BCL6 and prevent the unbridled increase of B cells	[72]
TAT-ETD	Hepatocarcinoma	CPP	HIF-1 activity and expression level reduction under hypoxia and finally reduced tumor growth by inhibiting angiogenesis	[73]